LRPAP Antibody [Alexa Fluor® 594]

• Reactivity: Hu
• Applications: WB, ICC/IF
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Alexa Fluor 594

LRPAP Antibody [Alexa Fluor® 594] Summary

• Immunogen: E. coli-derived recombinant human LRPAP
  Tyr35-Leu357
  Accession # P30533
• Specificity: Detects human LRPAP in direct ELISAs and Western blots. In Western blots, approximately 30% cross‑reactivity with recombinant mouse LRPAP is observed.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Immunocytochemistry
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for LRPAP Antibody [Alexa Fluor® 594]

• A2MRAP
• A2MRAPMRAP
• A2RAP
• alpha-2-macroglobulin receptor-associated protein 1
• alpha-2-macroglobulin receptor-associated protein
• alpha-2-MRAP
• HBP44
• lipoprotein receptor associated protein
• low density lipoprotein receptor-related protein associated protein 1
• Low density lipoprotein receptor-related protein-associated protein 1
• low density lipoprotein-related protein-associated protein 1(alpha-2-macroglobulin receptor-associated protein 1)
• LRPAP
• LRPAP1
• MGC138272
• RAP

Background

LRPAP (LDL receptor-related protein-associated protein 1; also named RAP), is a ubiquitously expressed 39 kDa chaperone for LDL receptor family proteins (1, 2). Mature human LRPAP shares 77% amino acid sequence identity with mouse and rat LRPAP. It is organized into three domains of comparable length. Domains D2 and D3 interact with each other, while D1 is independent (3). The D1 domain contains a low affinity binding site for LRP, and the associated D2 and D3 domains bind LRP with high affinity (4). The majority of LRPAP is localized in the endoplasmic reticulum and Golgi (5). LRPAP prevents the premature interaction of LRP, LRP2/megalin, and VLDLR with their coexpressed ligands, thereby promoting proper receptor folding and export from the ER (6‑8). Protonation of conserved histidine residues within the D3 domain induces the separation of LRPAP and LRP in the relatively acidic Golgi (9). LRPAP, which contains a C-terminal HNEL motif, can then recycle to the ER (9). A minor amount of LRPAP remains associated with LRP and can modulate receptor activity on the cell surface (5). Exogenously applied LRPAP competitively inhibits LDL receptor family binding and uptake of activated alpha 2-macroglobulin, apoB100- or apoE-enriched LDL and VLDL particles, cholesteryl esters, and complexes of PAI-1 with either tPA or uPA (10‑14).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.